{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GS&page=2", "query": { "condition": "GS", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=GS&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-07-23T07:23:24.834Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01457755", "title": "Gilead Sustained Virologic Response (SVR) Registry", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 6625, "start_date": "2012-04-13", "completion_date": "2018-01-08", "has_results": false, "last_update_posted_date": "2018-08-31", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 162, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 102 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457755" }, { "nct_id": "NCT01569295", "title": "Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Bendamustine", "type": "DRUG" }, { "name": "Placebo to match idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 416, "start_date": "2012-06-15", "completion_date": "2019-06-10", "has_results": true, "last_update_posted_date": "2020-03-10", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 23, "location_summary": "Huntsville, Alabama • Los Angeles, California • Palo Alto, California + 19 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Gainesville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01569295" }, { "nct_id": "NCT01193478", "title": "A Multiple Ascending Dose Study of GS 5885 in Previously Untreated Subjects With Genotype 1 Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "HCV Infection" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 71, "start_date": "2010-08", "completion_date": "2011-12", "has_results": false, "last_update_posted_date": "2013-01-21", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 13, "location_summary": "Anaheim, California • Cypress, California • National City, California + 10 more", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Cypress", "state": "California" }, { "city": "National City", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "DeLand", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01193478" }, { "nct_id": "NCT01457768", "title": "A Gilead Sequence Registry of Subjects Who Did Not Achieve Sustained Virologic Response", "overall_status": "COMPLETED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [], "intervention_types": [], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 570, "start_date": "2011-12-19", "completion_date": "2018-04-09", "has_results": false, "last_update_posted_date": "2018-05-04", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 158, "location_summary": "Birmingham, Alabama • Dothan, Alabama • Phoenix, Arizona + 89 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Birmingham", "state": "Alabama" }, { "city": "Dothan", "state": "Alabama" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01457768" }, { "nct_id": "NCT00350298", "title": "Study of the Clinical Effectiveness of a Human Monoclonal Antibody to C. Difficile Toxin A and Toxin B in Patients With Clostridium Difficile Associated Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Clostridium Infections" ], "interventions": [ { "name": "GS-CDA1/MDX-1388", "type": "BIOLOGICAL" }, { "name": "normal saline", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MassBiologics", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 200, "start_date": "2006-07-20", "completion_date": "2008-06-25", "has_results": true, "last_update_posted_date": "2021-02-09", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 22, "location_summary": "Los Angeles, California • Oakland, California • Newark, Delaware + 18 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Oakland", "state": "California" }, { "city": "Newark", "state": "Delaware" }, { "city": "Tampa", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00350298" }, { "nct_id": "NCT01384383", "title": "GS-5885, GS-9451 With Peginterferon Alfa 2a (PEG) and Ribavirin in Treatment-Naïve Subjects With Chronic Genotype 1 Hep C Virus Infection and IL28B CC Genotype", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Chronic Hepatitis C" ], "interventions": [ { "name": "GS-5885", "type": "DRUG" }, { "name": "GS-9451", "type": "DRUG" }, { "name": "RBV", "type": "DRUG" }, { "name": "PEG", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 248, "start_date": "2011-08", "completion_date": "2013-06", "has_results": false, "last_update_posted_date": "2014-02-03", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 26, "location_summary": "Los Angeles, California • Sacramento, California • San Diego, California + 20 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01384383" }, { "nct_id": "NCT00107003", "title": "GW572016 to Treat Recurrent Malignant Brain Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Glioma", "Brain Tumor", "Glioblastoma Multiforme", "GBM", "Gliosarcoma", "GS" ], "interventions": [ { "name": "lapatinib ditosylate", "type": "DRUG" }, { "name": "Adjuvant therapy", "type": "PROCEDURE" }, { "name": "Conventional surgery", "type": "PROCEDURE" }, { "name": "Neoadjuvant therapy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "PROCEDURE" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 9, "start_date": "2005-03-30", "completion_date": "2012-11-30", "has_results": false, "last_update_posted_date": "2018-07-05", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 1, "location_summary": "Bethesda, Maryland", "locations": [ { "city": "Bethesda", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107003" }, { "nct_id": "NCT07312006", "title": "Comparison of AirSeal to DV5 Insufflation in Gastric Sleeve Procedures - The \"CAT5-GS\" Study", "overall_status": "NOT_YET_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Pain, Postoperative" ], "interventions": [ { "name": "AirSeal Insufflation system", "type": "DEVICE" }, { "name": "DV5 Insufflation system", "type": "DEVICE" } ], "intervention_types": [ "DEVICE" ], "sponsor": "SurgiQuest, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "22 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "22 Years to 65 Years" }, "enrollment_count": 74, "start_date": "2026-01-30", "completion_date": "2027-01-01", "has_results": false, "last_update_posted_date": "2025-12-31", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 1, "location_summary": "Miami, Florida", "locations": [ { "city": "Miami", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT07312006" }, { "nct_id": "NCT04018417", "title": "Evaluation of Amphotericin B in Optisol-GS for Prevention of Post-Keratoplasty Fungal Infections.", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2", "PHASE3" ], "conditions": [ "Fuchs' Endothelial Dystrophy" ], "interventions": [ { "name": "Amphotericin B", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Cornea Research Foundation of America", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-07-03", "completion_date": "2019-07-03", "has_results": false, "last_update_posted_date": "2019-07-12", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 1, "location_summary": "Indianapolis, Indiana", "locations": [ { "city": "Indianapolis", "state": "Indiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT04018417" }, { "nct_id": "NCT01539512", "title": "A Randomized, Double-Blind, Placebo-Controlled Study of Idelalisib in Combination With Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Idelalisib", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Placebo to match idelalisib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Gilead Sciences", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 220, "start_date": "2012-04", "completion_date": "2014-04", "has_results": true, "last_update_posted_date": "2019-05-14", "last_synced_at": "2026-07-23T07:23:24.834Z", "location_count": 34, "location_summary": "Huntsville, Alabama • Tucson, Arizona • La Jolla, California + 27 more", "locations": [ { "city": "Huntsville", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "La Jolla", "state": "California" }, { "city": "Oxnard", "state": "California" }, { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT01539512" } ] }